To validate the excellent sensitivity (100%) of pan-TRK IHC in the 11 pan-TRK negative samples (Fig. 2), we additionally performed FFPE-TLC in the high NTRK fusions prevalent (22%) subgroup of mCRC patients with a MSI-H/dMMR, BRAF, and RAS wild-type tumor. This evidence concerns the gene BRAF and neoplasm.